As of 31 Dec 2025, 18 institutional investors reported holding $147,511,900 in principal (par value) of SAREPTA THERAPEUTICS INC - NOTE 1.250% 9/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $147,511,900 | $133,215,981 | -$243,157,718 | 89.64% | 18 |
| 2025 Q3 | $423,204,030 | $373,473,256 | -$483,579,093 | 87.97% | 30 |
| 2025 Q2 | $1,009,456,484 | $771,135,004 | -$30,695,954 | 73.38% | 57 |
| 2025 Q1 | $987,578,288 | $920,780,195 | +$32,593,408 | 93.16% | 75 |
| 2024 Q4 | $919,250,180 | $1,045,725,240 | -$29,748,516 | 110.1% | 77 |
| 2024 Q3 | $935,735,828 | $1,097,325,738 | -$3,339,388 | 113.6% | 72 |
| 2024 Q2 | $955,302,856 | $1,269,526,221 | -$95,435,668 | 128.9% | 75 |
| 2024 Q1 | $1,029,532,211 | $1,208,334,847 | +$7,418,505 | 116.91% | 63 |
| 2023 Q4 | $1,039,757,323 | $1,059,310,870 | +$23,391,526 | 101.51% | 64 |
| 2023 Q3 | $1,003,179,309 | $1,128,882,513 | +$1,128,882,326 | 112.15% | 64 |